Intrinsiqs

Is Avalo Therapeutics, Inc. overvalued?

Avalo Therapeutics, Inc. (AVTX) — key valuation metrics and fundamentals.

No verdict
Price
$15.08
Fair value
—
Current P/E
—
Normal P/E
—
Market cap
$792.7M
Dividend yield
0.0%
Return on equity
-58.0%
Sector
Healthcare

See the full interactive analysis →

Fair value compares AVTX's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 24 Sep 2026.